首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1566146

乳癌治療藥物市場規模、佔有率、成長分析、按治療方法、按癌症類型、按分銷管道、按地區 - 行業預測，2024-2031 年

Breast Cancer Therapeutics Market Size, Share, Growth Analysis, By Therapy, By Cancer Type, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月06日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年乳癌治療藥物市場規模為312.2億美元，從2023年的353億美元成長到2031年的945.3億美元，複合年成長率預計將成長13.1%。

目前，由於乳癌發病率上升以及人們對早期發現和治療重要性的認知不斷提高等多種因素的綜合作用，全球乳癌治療藥物市場正在強勁成長。醫療技術的創新和新治療方法的出現進一步推動市場擴張。一個顯著的趨勢是向個人化醫療和標靶治療的轉變，這顯著改善了患者的治療結果和生存率，HER2標靶治療和荷爾蒙療法的使用增加就是例證。免疫療法和聯合治療的開發也取得了進展，提供了療效提高的新治療途徑。此外，政府的支持措施以及對研發的大量投資以及製藥公司與研究機構之間的策略聯盟正在推動市場成長。然而，挑戰仍然存在，例如治療成本上升、潛在副作用以及某些地區獲得醫療保健的機會有限，這可能會阻礙整體市場的進步。儘管存在這些障礙，但由於治療方式的進步、社會意識的提高和醫療保健政策的加快，乳癌藥物市場正在蓬勃發展，這為改善患者預後和提高受影響個體的生活品質帶來了樂觀情緒。值得注意的是，美國乳癌治療市場預計在下一個預測期內將保持持續的複合年成長率，反映出其持續的成長潛力。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Genentech（F. Hoffmann-La Roche Ltd）
Eli Lilly and Company
Novartis AG
AstraZeneca
Pfizer Inc.
Sanofi
Eisai Co. Ltd.
Kyowa Kirin
Bristol Myers Squibb（Celgene Corporation）
Merck & Co., Inc.
Johnson & Johnson
AbbVie Inc.
Gilead Sciences
Takeda Pharmaceutical Company Limited
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Daiichi Sankyo Company, Limited
Otsuka Pharmaceutical Co., Ltd.
Ipsen

簡介目錄

Product Code: SQMIG35G2183

Breast Cancer Therapeutics Market size was valued at USD 31.22 billion in 2022 and is poised to grow from USD 35.30 billion in 2023 to USD 94.53 billion by 2031, growing at a CAGR of 13.1% in the forecast period (2024-2031).

The global breast cancer therapeutics market is currently witnessing robust growth, fueled by a confluence of factors that include the rising incidence of breast cancer and heightened awareness surrounding the importance of early detection and treatment. Innovations in medical technology and the emergence of novel therapies have further propelled market expansion. A notable trend is the shift towards personalized medicine and targeted therapies, exemplified by the increased use of HER2-targeted therapies and hormone therapies, which have significantly enhanced patient outcomes and survival rates. The development of immunotherapies and combination therapies is also making strides, presenting new avenues for treatment with improved efficacy. Furthermore, supportive government initiatives, along with substantial investments in research and development, and strategic collaborations between pharmaceutical firms and research institutions, are invigorating market growth. However, challenges persist, including the high costs of treatment, potential side effects, and limited healthcare access in certain regions, which could hinder overall market progress. Despite these obstacles, the breast cancer therapeutics market remains buoyed by advancements in treatment avenues, increased public awareness, and conducive healthcare policies, instilling optimism for better patient outcomes and quality of life for those affected by the disease. Notably, the US breast cancer therapeutics market is projected to maintain a sustainable compound annual growth rate (CAGR) over the next forecast period, reflecting continued growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Therapeutics Market Segmental Analysis

Global Breast Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Distribution Channel, and region. Based on Therapy, the market is segmented into Targeted Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Everolimus, Trastuzumab, Ribociclib, Palbociclib, Pertuzumab, Olaparib, Others), Hormonal Therapy (Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Downregulators (ERDs)), Chemotherapy, and Immunotherapy. Based on Cancer Type, the market is segmented into Hormone Receptor, HER2+. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Breast Cancer Therapeutics Market

A significant market driver for the global breast cancer therapeutics market is the escalating prevalence of breast cancer, which continues to rise worldwide due to various factors, including lifestyle changes and genetic predispositions. This alarming increase has spurred heightened awareness and the implementation of early detection programs, fostering a robust demand for innovative and effective treatment options. Furthermore, advancements in diagnostic techniques and the emergence of personalized medicine have paved the way for the development of targeted therapies, significantly enhancing patient outcomes. As a result, there is an urgent need for novel therapeutics, driving investment and research in this vital market segment.

Restraints in the Breast Cancer Therapeutics Market

The global breast cancer therapeutics market faces a significant restraint due to the high cost of treatment, which can limit patient access to effective therapies. Innovative drugs often come with steep price tags, compounded by the need for prolonged treatment regimens and supportive care, placing substantial financial burdens on patients and healthcare systems alike. Limited insurance coverage and restricted access to affordable treatment options further exacerbate this issue, creating barriers to necessary care. Moreover, the protracted and demanding processes involved in drug development and regulatory approval can hinder the timely introduction of new therapies, restricting options for patients in need.

Market Trends of the Breast Cancer Therapeutics Market

The Breast Cancer Therapeutics market is witnessing a significant trend toward personalized medicine and targeted therapies, driven by groundbreaking advancements in genomic research and molecular diagnostics. As the understanding of breast cancer's genetic and molecular characteristics deepens, the development of tailored therapies has emerged, allowing for treatments that are finely tuned to the individual patient's cancer profile. This shift not only enhances the efficacy of therapeutic interventions but also minimizes side effects, leading to improved patient outcomes. Consequently, the market is poised for continued growth, as healthcare providers increasingly adopt these innovative approaches to elevate cancer care in breast cancer patients.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Pricing Analysis
Value Chain Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Trade Analysis

Breast Cancer Therapeutics Market, By Therapy

Market Overview
Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
Immunotherapy

Breast Cancer Therapeutics Market, By Cancer Type

Market Overview
Hormone Receptor
HER2+

Breast Cancer Therapeutics Market, By Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Breast Cancer Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Genentech (F. Hoffmann-La Roche Ltd)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (Celgene Corporation)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments